Ignite Creation Date:
2025-12-24 @ 9:14 PM
Ignite Modification Date:
2026-01-04 @ 5:15 AM
Study NCT ID:
NCT03534804
Status:
COMPLETED
Last Update Posted:
2024-11-26
First Post:
2018-05-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
Sponsor:
University of Utah